Acetylcholine receptor subunit epsilon (CHRNE)

Acetylcholine receptor subunit epsilon (CHRNE) is a protein encoded by the CHRNE gene, forming a critical component of the muscle-type nicotinic acetylcholine receptor at the neuromuscular junction. This receptor is a ligand-gated ion channel responsible for transducing the binding of acetylcholine released from motor neurons into a rapid influx of cations and subsequent muscle contraction. In development, the epsilon subunit replaces the fetal gamma subunit at about the 33rd week of gestation, creating the adult-type receptor necessary for mature neuromuscular transmission. Mutations in CHRNE disrupt receptor assembly or function, leading to congenital myasthenic syndromes and muscle weakness. The receptor's structure and function are well-characterized, and its subunit composition, agonist binding sites, and channel properties have been defined. CHRNE is targeted indirectly by drugs improving neuromuscular transmission and, in some mutation-specific cases, by agents modifying channel open time or conductance. Clinical challenges relate to individualized drug responses and risk of adverse effects when manipulating synaptic signaling.

Other names

Cholinergic receptor nicotinic epsilon subunitACHREAchR epsilon subunitAcetylcholine receptor, nicotinic, epsilon (muscle)Cholinergic receptor, nicotinic, epsilon polypeptideACHE_HUMANCMS1A1CMS1DCMS1ECMS2ACMS4ACMS4BCMS4CFCCMSFIM1FIMGFIMG1MGISCCMSMyasthenia gravis, familial infantile, 1

Acetylcholinesterase inhibitors (increase acetylcholine at neuromuscular junction to augment signaling) Channel blockers (e.g., quinidine, fluoxetine, block prolonged opening in slow-channel CMS mutations) Adrenergic agonists (e.g., salbutamol, enhance neuromuscular transmission via unclear mechanisms)